Loading…

Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions

Research has recently focused on cognitive dysfunction in multiple sclerosis (MS). Cognitive deficits are frequently encountered in patients and account for important impairment in quality of life, therefore posing a major therapeutic challenge for the disease. We presently review studies on cogniti...

Full description

Saved in:

Bibliographic Details
Published in:	International review of psychiatry (Abingdon, England) England), 2010, Vol.22 (1), p.35-42
Main Authors:	Lyros, Epameinondas, Messinis, Lambros, Papageorgiou, Sokratis G., Papathanasopoulos, Panagiotis
Format:	Article
Language:	English
Subjects:	Cholinesterase Inhibitors - therapeutic use Clinical Trials as Topic Cognition Cognition Disorders - complications Cognition Disorders - drug therapy Cognition Disorders - epidemiology Cognitive ability Drug therapy Humans Immunomodulation Interferons - therapeutic use Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis - psychology Patients Psychopharmacology Quality of life
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c530t-11aa35f0f0f66924ae58ba5327ed7ac121a9058cf0fac6312e2fd4aebea83f0f3
cites	cdi_FETCH-LOGICAL-c530t-11aa35f0f0f66924ae58ba5327ed7ac121a9058cf0fac6312e2fd4aebea83f0f3
container_end_page	42
container_issue	1
container_start_page	35
container_title	International review of psychiatry (Abingdon, England)
container_volume	22
creator	Lyros, Epameinondas Messinis, Lambros Papageorgiou, Sokratis G. Papathanasopoulos, Panagiotis
description	Research has recently focused on cognitive dysfunction in multiple sclerosis (MS). Cognitive deficits are frequently encountered in patients and account for important impairment in quality of life, therefore posing a major therapeutic challenge for the disease. We presently review studies on cognitive effects of pharmacological treatments in MS. There is evidence for a possible beneficial effect of immunomodulatory treatments, particularly of interferons, and also of acetylcholinesterase inhibitors on cognition in MS, which, however, requires evaluation in larger, multi-centre, longitudinal studies. Methodological issues and future prospects regarding the investigation of this issue are also discussed.
doi_str_mv	10.3109/09540261003589455
format	article
fullrecord	<record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_journals_213233799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1998275141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-11aa35f0f0f66924ae58ba5327ed7ac121a9058cf0fac6312e2fd4aebea83f0f3</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7uzqD_AijRdPrZVk0h-6FxnWD1jwsoK3piZd2cmSTsYkvTL_3jSzKiqL1KGg6nlfqHoZe8bhleTQv4ZerUE0HECqrl8r9YCtuGz6mjeifchWy75egBN2mtINAAjF4TE7ESCEaLtmxb5uwrW32d5SNR6Smb3ONvjK-mqaXbZ7R1XSjmJINr2prnZUkTGkcxVMtd9hnFAHF66tRldEmeIt-cUhPWGPDLpET-_6Gfvy_uJq87G-_Pzh0-bdZa2VhFxzjiiVgVJN04s1kuq2qKRoaWxRc8GxB9XpskfdSC5ImLFQW8JOlqE8Yy-PvvsYvs2U8jDZpMk59BTmNLTrBtoWOP8_KWULUoimkC_-Im_CHH05YxBcisL1fYH4EdLlOSmSGfbRThgPA4dhiWf4J56ieX5nPG8nGn8pfuZRgPMjYL0J5bnfQ3TjkPHgQjQRvbZp8b7f_-0f8h2hyzuNkX5fcL_6B1FasGk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213233799</pqid></control><display><type>article</type><title>Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Lyros, Epameinondas ; Messinis, Lambros ; Papageorgiou, Sokratis G. ; Papathanasopoulos, Panagiotis</creator><creatorcontrib>Lyros, Epameinondas ; Messinis, Lambros ; Papageorgiou, Sokratis G. ; Papathanasopoulos, Panagiotis</creatorcontrib><description>Research has recently focused on cognitive dysfunction in multiple sclerosis (MS). Cognitive deficits are frequently encountered in patients and account for important impairment in quality of life, therefore posing a major therapeutic challenge for the disease. We presently review studies on cognitive effects of pharmacological treatments in MS. There is evidence for a possible beneficial effect of immunomodulatory treatments, particularly of interferons, and also of acetylcholinesterase inhibitors on cognition in MS, which, however, requires evaluation in larger, multi-centre, longitudinal studies. Methodological issues and future prospects regarding the investigation of this issue are also discussed.</description><identifier>ISSN: 0954-0261</identifier><identifier>EISSN: 1369-1627</identifier><identifier>DOI: 10.3109/09540261003589455</identifier><identifier>PMID: 20222786</identifier><identifier>CODEN: IRPSE2</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Cholinesterase Inhibitors - therapeutic use ; Clinical Trials as Topic ; Cognition ; Cognition Disorders - complications ; Cognition Disorders - drug therapy ; Cognition Disorders - epidemiology ; Cognitive ability ; Drug therapy ; Humans ; Immunomodulation ; Interferons - therapeutic use ; Multiple sclerosis ; Multiple Sclerosis - complications ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - psychology ; Patients ; Psychopharmacology ; Quality of life</subject><ispartof>International review of psychiatry (Abingdon, England), 2010, Vol.22 (1), p.35-42</ispartof><rights>2010 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2010</rights><rights>Copyright Taylor & Francis Ltd. 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-11aa35f0f0f66924ae58ba5327ed7ac121a9058cf0fac6312e2fd4aebea83f0f3</citedby><cites>FETCH-LOGICAL-c530t-11aa35f0f0f66924ae58ba5327ed7ac121a9058cf0fac6312e2fd4aebea83f0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010,27904,27905,27906,30980</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20222786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lyros, Epameinondas</creatorcontrib><creatorcontrib>Messinis, Lambros</creatorcontrib><creatorcontrib>Papageorgiou, Sokratis G.</creatorcontrib><creatorcontrib>Papathanasopoulos, Panagiotis</creatorcontrib><title>Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions</title><title>International review of psychiatry (Abingdon, England)</title><addtitle>Int Rev Psychiatry</addtitle><description>Research has recently focused on cognitive dysfunction in multiple sclerosis (MS). Cognitive deficits are frequently encountered in patients and account for important impairment in quality of life, therefore posing a major therapeutic challenge for the disease. We presently review studies on cognitive effects of pharmacological treatments in MS. There is evidence for a possible beneficial effect of immunomodulatory treatments, particularly of interferons, and also of acetylcholinesterase inhibitors on cognition in MS, which, however, requires evaluation in larger, multi-centre, longitudinal studies. Methodological issues and future prospects regarding the investigation of this issue are also discussed.</description><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Cognition</subject><subject>Cognition Disorders - complications</subject><subject>Cognition Disorders - drug therapy</subject><subject>Cognition Disorders - epidemiology</subject><subject>Cognitive ability</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Interferons - therapeutic use</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - complications</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis - psychology</subject><subject>Patients</subject><subject>Psychopharmacology</subject><subject>Quality of life</subject><issn>0954-0261</issn><issn>1369-1627</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqFkU2LFDEQhoMo7uzqD_AijRdPrZVk0h-6FxnWD1jwsoK3piZd2cmSTsYkvTL_3jSzKiqL1KGg6nlfqHoZe8bhleTQv4ZerUE0HECqrl8r9YCtuGz6mjeifchWy75egBN2mtINAAjF4TE7ESCEaLtmxb5uwrW32d5SNR6Smb3ONvjK-mqaXbZ7R1XSjmJINr2prnZUkTGkcxVMtd9hnFAHF66tRldEmeIt-cUhPWGPDLpET-_6Gfvy_uJq87G-_Pzh0-bdZa2VhFxzjiiVgVJN04s1kuq2qKRoaWxRc8GxB9XpskfdSC5ImLFQW8JOlqE8Yy-PvvsYvs2U8jDZpMk59BTmNLTrBtoWOP8_KWULUoimkC_-Im_CHH05YxBcisL1fYH4EdLlOSmSGfbRThgPA4dhiWf4J56ieX5nPG8nGn8pfuZRgPMjYL0J5bnfQ3TjkPHgQjQRvbZp8b7f_-0f8h2hyzuNkX5fcL_6B1FasGk</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Lyros, Epameinondas</creator><creator>Messinis, Lambros</creator><creator>Papageorgiou, Sokratis G.</creator><creator>Papathanasopoulos, Panagiotis</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>K9.</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>2010</creationdate><title>Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions</title><author>Lyros, Epameinondas ; Messinis, Lambros ; Papageorgiou, Sokratis G. ; Papathanasopoulos, Panagiotis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-11aa35f0f0f66924ae58ba5327ed7ac121a9058cf0fac6312e2fd4aebea83f0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Cognition</topic><topic>Cognition Disorders - complications</topic><topic>Cognition Disorders - drug therapy</topic><topic>Cognition Disorders - epidemiology</topic><topic>Cognitive ability</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Interferons - therapeutic use</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - complications</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis - psychology</topic><topic>Patients</topic><topic>Psychopharmacology</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lyros, Epameinondas</creatorcontrib><creatorcontrib>Messinis, Lambros</creatorcontrib><creatorcontrib>Papageorgiou, Sokratis G.</creatorcontrib><creatorcontrib>Papathanasopoulos, Panagiotis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>International review of psychiatry (Abingdon, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lyros, Epameinondas</au><au>Messinis, Lambros</au><au>Papageorgiou, Sokratis G.</au><au>Papathanasopoulos, Panagiotis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions</atitle><jtitle>International review of psychiatry (Abingdon, England)</jtitle><addtitle>Int Rev Psychiatry</addtitle><date>2010</date><risdate>2010</risdate><volume>22</volume><issue>1</issue><spage>35</spage><epage>42</epage><pages>35-42</pages><issn>0954-0261</issn><eissn>1369-1627</eissn><coden>IRPSE2</coden><abstract>Research has recently focused on cognitive dysfunction in multiple sclerosis (MS). Cognitive deficits are frequently encountered in patients and account for important impairment in quality of life, therefore posing a major therapeutic challenge for the disease. We presently review studies on cognitive effects of pharmacological treatments in MS. There is evidence for a possible beneficial effect of immunomodulatory treatments, particularly of interferons, and also of acetylcholinesterase inhibitors on cognition in MS, which, however, requires evaluation in larger, multi-centre, longitudinal studies. Methodological issues and future prospects regarding the investigation of this issue are also discussed.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>20222786</pmid><doi>10.3109/09540261003589455</doi><tpages>8</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0954-0261
ispartof	International review of psychiatry (Abingdon, England), 2010, Vol.22 (1), p.35-42
issn	0954-0261 1369-1627
language	eng
recordid	cdi_proquest_journals_213233799
source	Applied Social Sciences Index & Abstracts (ASSIA); Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects	Cholinesterase Inhibitors - therapeutic use Clinical Trials as Topic Cognition Cognition Disorders - complications Cognition Disorders - drug therapy Cognition Disorders - epidemiology Cognitive ability Drug therapy Humans Immunomodulation Interferons - therapeutic use Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis - psychology Patients Psychopharmacology Quality of life
title	Cognitive dysfunction in multiple sclerosis: The effect of pharmacological interventions
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T21%3A18%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cognitive%20dysfunction%20in%20multiple%20sclerosis:%20The%20effect%20of%20pharmacological%20interventions&rft.jtitle=International%20review%20of%20psychiatry%20(Abingdon,%20England)&rft.au=Lyros,%20Epameinondas&rft.date=2010&rft.volume=22&rft.issue=1&rft.spage=35&rft.epage=42&rft.pages=35-42&rft.issn=0954-0261&rft.eissn=1369-1627&rft.coden=IRPSE2&rft_id=info:doi/10.3109/09540261003589455&rft_dat=%3Cproquest_infor%3E1998275141%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c530t-11aa35f0f0f66924ae58ba5327ed7ac121a9058cf0fac6312e2fd4aebea83f0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213233799&rft_id=info:pmid/20222786&rfr_iscdi=true